Serum sodium and chloride interplay and the effect of empagliflozin in heart failure: an EMPEROR-Pooled analysis.
Chloride measurement improves heart-failure risk prediction, though it doesn't change whether sodium-glucose inhibitors help patients.
A pooled trial analysis examined serum sodium and chloride as prognostic markers and treatment modifiers in ambulatory heart failure. Chloride added prognostic information, but electrolyte status did not alter the observed benefit of empagliflozin.
What the study was
- Study design
- Pooled secondary analysis of randomized heart-failure trials
- Population
- Ambulatory patients with heart failure in the EMPEROR trials
- Category
- Treatment Innovation
- Maturity
- Validated
- Journal
- Clinical research in cardiology : official journal of the German Cardiac Society
Why it surfaced
Large trial-derived clinical data refine heart-failure risk interpretation and support consistent SGLT2 benefit.
A plain-language summary of published research — not medical advice. Talk to a clinician about your own care.